Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Division of Psychosomatic Medicine, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Hiromichi
H
Matsuoka
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Department of Medical Oncology, Kishiwada City Hospital, Osaka, Japan. Electronic address: kaneda_h@dotd.med.kindai.ac.jp.
Hiroyasu
H
Kaneda
Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Kazuko
K
Sakai
Division of Psychosomatic Medicine, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Atsuko
A
Koyama
Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Kazuto
K
Nishio
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Kazuhiko
K
Nakagawa
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use; D000068338:Everolimus / Q000009:adverse effects* / Q000627:therapeutic use; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000235:genetics; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000175:diagnosis* / Q000209:etiology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009154:Mutation / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000068338:Everolimus; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib
EGFR mutation; EGFR-TKI to non-small cell lung cancer and mTOR; Non-small cell lung cancer; Primary resistance; mTOR